. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clinical Pharmacology and Therapeutics, 84 (1) This study aimed to quantify the inhibition of CYP3A, CYP2D6 and P-glycoprotein in HIVinfected patients receiving an antiretroviral therapy containing ritonavir boosted lopinavir, and to identify factors influencing ritonavir and lopinavir pharmacokinetics.
Introduction
In the treatment of HIV-infected patients, most antiretroviral therapy regimens include protease inhibitors, of which ritonavir boosted lopinavir (Kaletra®) is among the most widely used (1) . Lopinavir has a negligible bioavailability unless the cytochrome P450 (CYP) 3A enzymes, which mediate its extended first pass metabolism, are inhibited by low-dose ritonavir. In vitro investigations, studies in laboratory animals and in healthy volunteers suggest that ritonavir boosted lopinavir influences the activities of other enzymes like CYP2D6, the second most important drug metabolizing CYP enzyme in the liver, and of drug transporters like the efflux transporter P-glycoprotein (2) (3) (4) (5) . Thus, beyond (necessary) CYP3A inhibition, ritonavir boosted lopinavir is at risk to cause drug-drug interactions by inhibition of several other structures. In HIV infected patients, however, the effect of the combination on enzyme and transporter activities has not yet been quantified.
As an additional problem, pharmacokinetics of protease inhibitors (PI) show high interindividual variability that may cause suboptimal drug exposure, poor treatment response or toxicity. The knowledge of factors which influence this variability may be useful to optimize HIV therapy. Only few in vivo trials focus on the influence of the individual activities of CYP3A, CYP2D6 and P-glycoprotein on PI pharmacokinetics (2, 4, (6) (7) (8) . Most of these studies have been carried out in healthy volunteers or in laboratory animals.
The activities of CYP3A, CYP2D6, and P-glycoprotein are in part genetically determined.
Functionally deficient CYP2D6 and the CYP3A5*3 alleles were associated with alterations in the metabolism of some PIs (9) (10) (11) (12) , while for relationships between P-glycoprotein genotypes and pharmacokinetics of different PIs, results are contradictory (12) (13) (14) (15) (16) (17) . For lopinavir and ritonavir, information on genetic influences is sparse.
Hence, the present study had two aims. One purpose was to quantify the effect of ritonavir boosted lopinavir on the activities of the most important cytochrome P450 enzymes, namely CYP3A at the intestinal and the hepatic expression sites, CYP2D6, and of P-glycoprotein in HIV-infected individuals. The other purpose was to identify factors of influence on the pharmacokinetics of ritonavir and lopinavir which may be used for a-priori dose individualization. To this end, the combined impact of demographic factors, genetic polymorphisms and the activities of CYP3A, CYP2D6, and P-glycoprotein on the pharmacokinetics of lopinavir and ritonavir was assessed.
Material and Methods:

Study design and study population
This prospective, open, non-randomized, two-period trial was conducted in 30 male and female treatment-naïve HIV-infected patients, of which 28 completed the trial (table 1). The activities of hepatic and intestinal CYP3A, CYP2D6 and P-glycoprotein were investigated twice by using a phenotyping cocktail, once before (period 1), and once at least 14 days after the start (period 2) of an antiretroviral regimen (ART) containing 400 mg lopinavir + 100 mg ritonavir (3 capsules Kaletra®, Abbott, Wiesbaden, Germany) twice daily. Together with Kaletra®, the nucleoside reverse transcriptase inhibitors zidovudine and lamivudine (300 mg and 150 mg, respectively, twice daily, Combivir®, GlaxoSmithKline, Munich, Germany)
were started in all patients. The subjects were asked regularly about adherence to the antiretroviral therapy. All drug intakes on the phenotyping days were supervised. The main exclusion criteria were: any relevant pathological finding not explained by the HIV infection, any relevant history or current condition that might interfere with pharmacokinetics, hepatic or renal diseases or dysfunctions, drug and alcohol abuse, pregnancy and breast-feeding.
Patients using a medication or natural product (including grapefruit and herbal remedies) known to potentially interfere with CYP3A, CYP2D6 and P-glycoprotein were not included.
The study was endorsed by the Ethics Committee of the University of Cologne, Germany, and conducted in accordance with the laws of Germany. Written informed consent was obtained from each patient.
The phenotyping cocktail consisted of 1.5 mg midazolam hydrochloride (CYP3A, Dormicum® V 5mg/5mL, Hoffmann-La Roche, Grenzach-Wyhlen, Germany), 30 mg dextromethorphan hydrobromide (CYP2D6, Hustenstiller-ratiopharm®, ratiopharm, Ulm, Germany), and 0.5 mg digoxin (P-glycoprotein, Lanicor®, Roche) administered orally in the morning either alone or together with the antiretrovirals. Four hours later, 1.0 mg midazolam hydrochloride (hepatic CYP3A, Dormicum®, Roche), was given intravenously. Midazolam is the best validated probe for CYP3A activity both at the hepatic and the intestinal expression sites. Dextromethorphan and digoxin are established probes for CYP2D6 and P-glycoprotein activity, respectively (18) (19) (20) . Midazolam, digoxin, dextromethorphan, and dextrorphan were quantified in plasma before and up to 12 h after oral dosing (22 samples). Only during period 2, lopinavir and ritonavir were quantified in plasma up to 12 h after the morning dose of Kaletra® (11 samples). Plasma was stored at -80°C until analysis.
Analytical methods
Midazolam, dextromethorphan, and dextrorphan in plasma
After thawing, 300 µL of 100 mM NaHCO 3 (pH 10.5), 50 µL water, and 50µL of internal 
Lopinavir and ritonavir in plasma
Both analytes were quantified in plasma using a HPLC-UV method with a lower limit of quantification of 0.07 mg/L for lopinavir and 0.05 mg/L for ritonavir as described (21) .
Digoxin in plasma
Digoxin concentrations were measured on a Roche/Hitachi MODULAR P analyzer using the Tina-quant® digoxin immunoassay (Roche Diagnostics GmbH, Mannheim, Germany), with a lower limit of quantification of 0.15 ng/mL.
Genotyping
Genomic DNA from EDTA containing blood samples was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Analyses for the CYP2D6 alleles *3, *4, *5, *6, and the duplication allele were performed with PCR-RFLP-methods as described (22) .
Determination of these non-functional CYP2D6 alleles has been shown to be sufficient to correctly identify 95% of the poor metabolizers (PM) according to CYP2D6 (22) . Individuals were assessed to the PM group when carrying two inactive CYP2D6 alleles (CYP2D6*3, *4, *5, or *6), to the intermediate (IM) group when carrying one active and one inactive allele (heterozygous carrier), to the extensive metabolizer (EM) group when none of the variant alleles was found, and to the ultrarapid metabolizer (UM) group when carrying a CYP2D6
gene duplication in combination with two active alleles.
Genotyping for the CYP3A5*3 allele was done as described using a melting curve analysis technique (23, 24) . Sequencing analysis was performed on a Genetic Analyzer 3100 capillary sequencer (Applied Biosystems) and pairwise sequence alignments were done with GenBank sequence NM_000927 using MT Navigator PPC and Edit View software (Applied Biosystems).
Pharmacokinetic calculations
Noncompartmental methods were used for pharmacokinetic analysis (WinNonlin TM Professional 5.0.1, Pharsight corp., Cary, NC), except for midazolam. The areas under the plasma concentration time curves (AUC) were calculated using the log-linear method.
Pharmacokinetics of lopinavir and ritonavir were assessed during one dosing interval in steady-state. For digoxin, dextromethorphan, and dextrorphan, AUC values from dosing up to 12 h thereafter without extrapolation to infinity were reported. The early portion of the digoxin AUC and the digoxin C max have been used earlier as parameters to characterize the intestinal P-glycoprotein activity (25) (26) (27) . The fraction of AUC dextromethorphan and AUC dextrorphan based on extrapolation was above 20% in most subjects and varied considerably between subjects, which justified the use of AUC values without extrapolation, since most dextromethorphan-based CYP2D6 phenotyping metrics proposed in literature are based on parameters obtained up to 8 h after dosing (19) . As a parameter for CYP2D6 activity, the molar ratio of the plasma AUC dextromethorphan over the plasma AUC dextrorphan was chosen. The individual activity of (intestinal) P-glycoprotein was assessed with the digoxin AUC 0-12h and the digoxin C max values.
To estimate the CYP3A activity separately for the intestinal and hepatic expression sites, the pharmacokinetics of midazolam were assessed with a compartmental approach by population pharmacokinetic analysis using the nonlinear mixed effect modeling program NONMEM® version V (level 1.1, GloboMax, Ellicot City, MD) as described earlier (28). Briefly, a one compartment model without intraindividual variation was stepwise expanded to more complex models. The best model was a two-compartment model with first-order absorption (subroutine ADVAN4 TRANS4), interindividual variation in each parameter except in intercompartmental clearance and peripheral volume of distribution, and appropriate error modeling for the interindividual and the residual variability (which included intraindividual variability). The midazolam clearance after intravenous dosing (a standard parameter for hepatic CYP3A activity) and the oral midazolam availability (F) were directly modeled by the program and were estimated separately for each study period. The apparent oral midazolam clearance was calculated as Cl / F, and reflects both hepatic and intestinal CYP3A activities.
As parameter for intestinal CYP3A activity, the intestinal midazolam availability (i.e. the ratio of oral availability over hepatic availability) was calculated as described earlier (28,29).
Individual doses were calculated from weights of the application devices with and without midazolam solutions, and were included in the analysis.
Statistical analysis
Values are given as geometric means and geometric coefficients of variation unless otherwise stated. A p-value of <0.05 was considered statistically significant. The interactions between antiretroviral therapy and phenotyping probes were evaluated as a bioequivalence problem (30). Point estimates for the true ratios of individual parameters in the periods without (reference) and with antiretrovirals (test) and the corresponding 90% confidence intervals (CI)
were calculated. An interaction was assumed to be absent when both the point estimate and the 90% CI were entirely within the bioequivalence boundaries of 80 -125 % of the reference values.
For comparisons between two variables, correlation analyses, Mann-Whitney-U tests, or
Kruskal-Wallis tests were carried out. Univariate linear effect models were used to investigate the extent of influence of i) demographics and genetics on the activities of CYP3A, CYP2D6
and P-glycoprotein, and ii) demographics, genetics, enzyme and transporter activities on lopinavir and ritonavir pharmacokinetics. An influence was judged as clinically relevant if it explained 30% or more of the interindividual variability. No adjustment for multiple testing page 11
was done, since the target variables were considered mutually independent, however, several potential covariates were tested for one target, so that the models were exploratory in nature.
As factors of potential influence, age, weight, height, Body Mass Index, transporter and enzyme activities were included as covariates, while gender, race, and genotypes were included as fixed factors. For statistical analysis, WinNonlin TM and SPSS®, release 11.0.1 (SPSS Inc., Chicago, IL) were used.
Sample size calculation
A sample size of 30 patients was calculated using WinBiAS (Version 7.01, epsilon Verlag, Darmstadt, Germany) and allowed to test whether the interindividual variability in PI pharmacokinetics was determined to at least 30% each by CYP3A, CYP2D6 or Pglycoprotein activity with a power of 90% on a significance level of 0.05 using linear correlation analysis.
Results
After at least two weeks of twice daily intake of 400 mg lopinavir and 100 mg ritonavir (3 capsules Kaletra®) together with zidovudine and lamivudine, the parameters for CYP3A activity showed profound enzyme inhibition ( figure 1, figure 2, Two patients did not participate in the second study period, one because of staying abroad for a longer time and the other because of intercurrent AIDS related diseases requiring treatment with drugs not allowed in the protocol. The study procedures and drugs were well tolerated.
Discussion
In this study in HIV infected patients treated with ritonavir boosted lopinavir, lamivudine, and zidovudine, we quantified the extent of inhibition separately for hepatic and intestinal CYP3A, for CYP2D6, and for P-glycoprotein using a cocktail consisting of well-established phenotyping probes (18, 20, 26) . For CYP3A and P-glycoprotein, this study confirmed the profound extent of inhibition by ritonavir boosted lopinavir already observed in healthy volunteers and in vitro (4,7,31). Additionally, we observed changes in dextromethorphan metabolism which indicated potent inhibition of CYP2D6. We attribute these effects mainly to ritonavir with some contribution of lopinavir, because for lamivudine and zidovudine, no interactions with the proteins studied here are reported in literature and their molecular structure does not suggest binding to CYPs or P-glycoprotein.
The combined hepatic and intestinal CYP3A and the hepatic CYP3A activities decreased by 81.5% and by 76.1%, respectively, which is similar to previous results in healthy volunteers:
decreases by 92% and by 77%, respectively, were observed (4). In a study with seven patients receiving ritonavir in higher doses, the overall CYP3A activity was also distinctively decreased (7) . A separate estimation of changes in intestinal CYP3A activity caused by ritonavir boosted lopinavir has not yet been reported. In the present study, an inhibition of intestinal CYP3A was observed in most patients, but in some participants, the parameter changed into the opposite direction (fig 2, mid panel) , so that the mean decrease in intestinal CYP3A activity was modest. In vitro, ritonavir very potently inhibits CYP3A with IC 50 values between 0.07 and 2.0 μM (32). In conclusion, interactions by ritonavir boosted lopinavir via CYP3A observed in studies with healthy volunteers will be the same in HIV infected patients.
The changes in dextromethorphan based plasma pharmacokinetics in the 24 patients with at least one active CYP2D6 allele suggested that CYP2D6 activity was inhibited in the present study. Not only the increase in the metabolic ratio, but also the increase in AUC dextromethorphan and the decrease in AUC dextrorphan support this conclusion. In a study with 13 healthy males who were phenotyped before and at the end of twice daily intake of 100 mg ritonavir for 2 weeks, a modest inhibition of CYP2D6 was observed with desipramine, another CYP2D6
substrate (mean 26% increase in desipramine AUC), but no change in CYP2D6 activity was noted using dextromethorphan-based urinary metabolic ratios (2) . Another study in healthy volunteers did not find any influence of ritonavir boosted lopinavir on desipramine pharmacokinetics (3). In contrast, in vitro investigations suggested potent CYP2D6 inhibition by ritonavir (IC 50 : 2.5 μM) (32).
The contradictory findings concerning CYP2D6 inhibition by ritonavir using the desipramine AUC and the urinary dextromethorphan / dextrorphan ratio (2) raise the question which metric most reliably reflects changes in CYP2D6 activity (33-35). While desipramine is a less frequently used CYP2D6 probe with limited applicability in a phenotyping cocktail, the urinary dextromethorphan ratio is dependent on urinary pH (36), and is not sensitive to detect minor changes (33). The "gold standard" for enzyme activity assessment would be the quantification of the CYP2D6 mediated fractional metabolic clearance. Since this parameter cannot be quantified directly, as an approximation, we decided to use the dextromethorphan / dextrorphan AUC ratio which has been proposed as a more sensitive parameter of CYP2D6 activity than urine-based metrics (33), but also has some limitations (19) . The relatively low within-subject variability in dextromethorphan pharmacokinetics in our study (e.g. 21.8% for the metabolic ratio) corroborates the validity of the approach chosen.
Further evidence for an inhibition of CYP2D6 by ritonavir boosted lopinavir comes from case reports of unanticipated drug toxicity. In two reports, extrapyramidal toxicity of risperidone was described (37, 38) , which is to at least 80% metabolized via CYP2D6 (39) . At least three reports describe life-threatening toxicities of methylene-dioxy-methamphetamine (MDMA, ecstasy, reviewed in (40)). The first and rate-limiting step in MDMA biotransformation is mediated by CYP2D6 (41) . Taken together, the present results support a relevant inhibition of CYP2D6 by ritonavir boosted lopinavir which may have clinically relevant implications for drugs with a narrow therapeutic index.
The changes in AUC ratios in the four poor metabolizers, who do not express CYP2D6, cannot be attributed to CYP2D6 inhibition. Other pathways of metabolism and elimination of dextromethorphan become relevant if CYP2D6 activity is absent, like glucuronidation of metabolites (19, 42, 43) . Ritonavir inhibits glucuronidation (44) , but induction of glucuronidation by ritonavir in steady-state has been described (45) , and recently been shown in an interaction study with lamotrigine (46) . However, the extent and direction of changes in the four poor metabolizers was highly variable, and the number was too small to draw conclusions. The 1.81-fold increase of digoxin AUC 0-12 during antiretroviral therapy suggests that Pglycoprotein activity was profoundly inhibited. A study in 12 healthy volunteers who received 300 mg ritonavir twice daily for 11 days showed a 1.86-fold increase in digoxin AUC 0-∞ (31).
It may be concluded that higher doses of ritonavir do not lead to a more complete inhibition of P-glycoprotein. Additionally, orally administered digoxin appears to mainly quantify the intestinal P-glycoprotein activity (25-27).
It has been postulated repeatedly that genetics, enzyme and transporter phenotypes, and other factors influence the variability in protease inhibitor pharmacokinetics. (4, (6) (7) (8) (9) 11, 32, 47) . In the present study, besides a small, but statistically significant, contribution of CYP2D6 genotypes to the interindividual variability in ritonavir C max , we could not detect significant influences of genotypes on lopinavir or ritonavir pharmacokinetics. Interestingly, the overall CYP3A activity influenced ritonavir exposure, indicating a dependency between the extent of CYP3A inhibition and ritonavir pharmacokinetics. However, none of the phenotypes assessed before treatment was predictive for the extent of inhibition during ART or for protease inhibitor pharmacokinetics, preventing dose individualization by phenotyping. Although 11%
of the interindividual variability in lopinavir exposure was explained by age, this fraction may be too small for dose individualization. Previous investigations did not find relationships between age and single-time-point lopinavir plasma concentrations (48, 49) , but exposure is a more reliable target parameter to identify factors of influence on pharmacokinetics. It should be noted that we investigated patients, which may have introduced some additional variability and necessitated that the patients took lamivudine and zidovudine as part of their antiretroviral therapy. Additionally, as a function of variability and sample size, small, probably clinically not relevant influences may have been missed. Great care was taken that no potentially interacting medication was taken and that patients adhered to the standardization measures.
In conclusion, an antiretroviral regimen containing ritonavir boosted lopinavir besides zidovudine and lamivudine inhibits the CYP2D6 dependent drug metabolism in HIV infected patients in addition to the pronounced inhibitions of CYP3A at both the intestinal and hepatic expression sites, and of (intestinal) P-glycoprotein. This underlines the potential risk of interactions between ritonavir boosted lopinavir and drugs with a narrow therapeutic index that are CYP2D6 substrates. The impact of genetic polymorphisms in CYP3A5, CYP2D6 and MDR1 on the pharmacokinetics of ritonavir boosted lopinavir appears negligible.
Additionally, phenotyping of CYP3A, CYP2D6 and P-glycoprotein activity before initiation of the antiretroviral therapy was not useful to predict lopinavir and ritonavir pharmacokinetics a priori. Hence, the covariates and factors investigated do not contribute relevantly to the pharmacokinetic variability of ritonavir boosted lopinavir in HIV-infected patients. Selection of doses based on these parameters does not appear to be a promising approach. 
